Filing Details
- Accession Number:
- 0001209191-16-097454
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-10 19:39:31
- Reporting Period:
- 2016-02-08
- Filing Date:
- 2016-02-10
- Accepted Time:
- 2016-02-10 19:39:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1571498 | Epizyme Inc. | EPZM | Pharmaceutical Preparations (2834) | 261349956 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1632720 | E. Andrew Singer | C/O Epizyme, Inc. 400 Technology Square Cambridge MA 02139 | Evp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 | Acquisiton | 2016-02-09 | 20,183 | $0.00 | 20,183 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 | Acquisiton | 2016-02-09 | 9,329 | $0.00 | 29,512 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 | Disposition | 2016-02-10 | 12,158 | $9.54 | 17,354 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2016-02-08 | 76,400 | $0.00 | 76,400 | $8.98 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2016-02-09 | 80,732 | $0.00 | 80,732 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2016-02-09 | 20,183 | $0.00 | 20,183 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2016-02-09 | 9,329 | $0.00 | 9,329 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 76,400 | 2026-02-08 | No | 4 | A | Direct | |
| 80,732 | No | 4 | A | Direct | ||
| 60,549 | No | 4 | M | Direct | ||
| 27,984 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting.
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.99 per share to $9.95 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- This option was granted on February 8, 2016 pursuant to the Company's 2013 Stock Incentive Plan with respect to 76,400 shares of Common Stock, with 25% vesting on February 8, 2017 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
- This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
- This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
Billionaire Hedge Funds
